GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has received an order dated 21st January 2026 from the Deputy Commissioner of CGST & Central Excise, Indore, disallowing certain GST input tax credits claimed in Madhya Pradesh. The total demand is Rs. 3.79 crore, comprising Rs. 1.90 crore in tax and an equal amount in penalty, with interest yet to be quantified. The demand covers FY 2019-20 through FY 2022-23. The company says there is no material impact on its financial operations and is evaluating the order to decide on further action, which may include appeal.
The demand amount of Rs. 3.79 crore is small relative to GSK Pharma's overall scale and is unlikely to move the stock. The disclosure is a procedural compliance item, and the final outcome will depend on the company's response and any appeal filed.